A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas
- PMID: 16626826
- DOI: 10.1016/j.radonc.2006.03.010
A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas
Abstract
Background and purpose: This phase II study evaluated the efficacy and toxicity of weekly cisplatin along with concomitant boost accelerated radiation regimen in patients with locally advanced unresectable head and neck carcinoma.
Material and methods: A total of 94 patients (median age, 58 years) with UICC stage III (n = 19) and IV (n = 75) cancer of the oropharynx, larynx, hypopharynx and oral cavity were included. Patients received radiotherapy with a concomitant boost scheme (1.8 Gy on days 1-40 and 1.5 Gy boost on days 25-40 with a total dose of 72 Gy) and concurrent cisplatin, 40 mg/m(2) weekly, for the first 4 weeks.
Results: Most patients (95%) received both radiation and chemotherapy according to protocol. Toxicity was manageable with grade III mucositis and pharyngeal-oesophageal toxicity in 85 and 50% of patients, respectively. Haematological toxicity was mild. Four patients (4%) died due to complications. With a median follow of 41 months, median overall survival and time to progression were 27 and 25 months, respectively. The estimated overall survival at 4 years was 41%.
Conclusions: Concomitant boost accelerated radiation plus concurrent weekly cisplatin is a feasible schedule in patients with locally advanced unresectable head and neck carcinoma, with acceptable toxicity and survival data.
Similar articles
-
Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.J Clin Oncol. 2005 May 1;23(13):3008-15. doi: 10.1200/JCO.2005.12.060. J Clin Oncol. 2005. PMID: 15860857 Clinical Trial.
-
Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.Head Neck. 2005 Jan;27(1):36-43. doi: 10.1002/hed.20111. Head Neck. 2005. PMID: 15459918 Clinical Trial.
-
A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract.Cancer. 2005 Feb 1;103(3):559-68. doi: 10.1002/cncr.20803. Cancer. 2005. PMID: 15597408 Clinical Trial.
-
Evidence-based radiation oncology in head and neck squamous cell carcinoma.Radiother Oncol. 2007 Oct;85(1):156-70. doi: 10.1016/j.radonc.2007.04.002. Epub 2007 May 4. Radiother Oncol. 2007. PMID: 17482300 Review.
-
A long-term follow-up study after split-course irradiation with concurrent chemotherapy (carboplatin) for locally advanced head and neck cancer and a review of the literature.ORL J Otorhinolaryngol Relat Spec. 2004;66(6):325-31. doi: 10.1159/000081890. ORL J Otorhinolaryngol Relat Spec. 2004. PMID: 15668532 Review.
Cited by
-
Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma.Front Oncol. 2019 Aug 27;9:815. doi: 10.3389/fonc.2019.00815. eCollection 2019. Front Oncol. 2019. PMID: 31508372 Free PMC article. Review.
-
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.J Natl Cancer Inst. 2019 May 1;111(5):490-497. doi: 10.1093/jnci/djy133. J Natl Cancer Inst. 2019. PMID: 30239887 Free PMC article.
-
Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin.Clin Transl Oncol. 2013 Apr;15(4):321-6. doi: 10.1007/s12094-012-0925-9. Epub 2012 Aug 22. Clin Transl Oncol. 2013. PMID: 22911552 Clinical Trial.
-
Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma.Clin Med Insights Oncol. 2021 Oct 4;15:11795549211048417. doi: 10.1177/11795549211048417. eCollection 2021. Clin Med Insights Oncol. 2021. PMID: 34629923 Free PMC article.
-
Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival.Int Arch Otorhinolaryngol. 2017 Apr;21(2):171-177. doi: 10.1055/s-0036-1594020. Epub 2016 Dec 19. Int Arch Otorhinolaryngol. 2017. PMID: 28382126 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
